Examkin

Question

Difficulty: HardPharmacologic Interventions

A 5252-year-old man is hospitalized for a 55-day history of right-sided pleuritic chest pain, nonproductive cough, and subjective fevers. Eighteen months ago, he underwent bilateral lung transplantation for idiopathic pulmonary fibrosis. His daily medications include tacrolimus, mycophenolate mofetil, prednisone, and pantoprazole. He is also receiving therapeutic subcutaneous enoxaparin for a provoked deep vein thrombosis diagnosed 33 weeks ago.

Vital signs show a temperature of 38.2∘C38.2^\circ\text{C} (100.8∘F100.8^\circ\text{F}), heart rate of 98/min98/\text{min}, blood pressure of 135/85 mm Hg135/85\text{ mm Hg}, and respiratory rate of 18/min18/\text{min}. Oxygen saturation is 96%96\% on room air.

Laboratory studies are as follows:
Leukocyte count: 6,500/mm36,500/\text{mm}^3
Platelet count: 180,000/mm3180,000/\text{mm}^3
Serum creatinine: 1.1 mg/dL1.1\text{ mg/dL}
Aspartate aminotransferase (AST): 24 U/L24\text{ U/L}
Alanine aminotransferase (ALT): 28 U/L28\text{ U/L}

A chest computed tomography (CT) scan reveals a dense 3-cm3\text{-cm} consolidation in the right upper lobe surrounded by a halo of ground-glass attenuation. Serum galactomannan assay is markedly elevated. The patient is diagnosed with invasive pulmonary aspergillosis, and the decision is made to initiate intravenous voriconazole.

Which of the following is the most appropriate concurrent pharmacologic intervention?

  1. Reduce the maintenance dose of tacrolimusAnswer
  2. B
    Increase the maintenance dose of tacrolimus
  3. C
    Transition the enoxaparin to oral rivaroxaban
  4. D
    Add intravenous micafungin to overcome intrinsic azole resistance
  5. E
    Discontinue mycophenolate mofetil due to the current leukocyte count

Answer

The most appropriate concurrent pharmacologic intervention is to reduce the maintenance dose of tacrolimus.
The correct intervention is to reduce the maintenance dose of tacrolimus. Voriconazole, the primary treatment for invasive pulmonary aspergillosis, is a potent inhibitor of cytochrome P450 3A4 (CYP3A4). Tacrolimus is a calcineurin inhibitor with a narrow therapeutic index that relies heavily on CYP3A4 for metabolism. Coadministration of voriconazole without adjusting the tacrolimus dose will cause a profound accumulation of tacrolimus, precipitating severe acute kidney injury, neurotoxicity (e.g., tremors, seizures), and hemodynamic instability. Standard clinical protocol dictates preemptively reducing the tacrolimus dose by 50%50\% to 75%75\% when initiating voriconazole, followed by meticulous therapeutic drug monitoring of trough levels.

Step-by-Step Solution

1
Identify the primary diagnosis and the medical team's planned treatment.
The patient has invasive pulmonary aspergillosis (halo sign on CT, positive galactomannan) and will be started on voriconazole.
Establishing the new pharmacologic agent is required to evaluate potential drug-drug interactions with the patient's baseline regimen.
2
Analyze the pharmacokinetic profile of the newly planned medication.
Voriconazole is recognized as a potent inhibitor of the cytochrome P450 3A4 (CYP3A4) enzyme system.
CYP3A4 inhibition drastically alters the clearance of concurrent medications metabolized by this pathway.
3
Cross-reference the patient's existing medication list for CYP3A4 substrates.
Tacrolimus is a narrow-therapeutic-index medication that is heavily metabolized by CYP3A4.
Identifying the vulnerable substrate allows the clinician to predict the direction of the interaction (inhibition leads to substrate accumulation).
4
Formulate a management strategy for the identified drug-drug interaction.
The dose of tacrolimus must be preemptively reduced (typically by 50% to 75%) and trough levels monitored closely.
Failure to reduce the dose will result in toxic accumulation of tacrolimus, leading to severe nephrotoxicity, neurotoxicity, and potential graft dysfunction.

Key Concept

Preemptive dose reduction of calcineurin inhibitors (tacrolimus, cyclosporine) is mandatory when initiating potent CYP3A4 inhibitors (such as voriconazole) to prevent severe, life-threatening toxicity.
Rate this question

Topics

Pharmacologic Interventions

More questions from this topic